Pediatric Pain Trials Beget Novel Approaches

September 2011
Hospice Management Advisor;Sep2011, Vol. 16 Issue 9, p107
The article discusses that more pediatric pain trials need to be carried out as using adult clinical data cannot assure the safety of using pain medications in children. Gary Walco, director of pain medicine at Seattle Children's Hospital comments on a peer-reviewed unpublished paper, which addresses the issues in children's pain medication. Ethical and other issues in pediatric pain trials, which need to be considered by institutional review boards (IRBs) are also discussed.


Related Articles

  • Pediatric pain trials beget novel approaches.  // IRB Advisor;Aug2011, Vol. 11 Issue 8, p93 

    The article discusses the challenges involved in designing clinical trials examining the pediatric pain medications while highlighting the issues that should be considered by the institutional review boards (IRBs) while reviewing such studies. It also mentions new guidelines for pediatric pain...

  • Pressure Grows to Publish Data. Ward, Philip // Applied Clinical Trials;Nov2010, Vol. 19 Issue 11, p18 

    The article reports on the existing regulations concerning the publication of clinical trial results in the U.S. It states that the implementation of data measures should include trials of drug and non-drug interventions to enable better decision making in healthcare. It notes that the...

  • Protocol Amendments: A Costly Solution. Getz, Kenneth A. // Applied Clinical Trials;May2011, Vol. 20 Issue 5, p28 

    The article offers insights on the cost needed to enforce protocol amendments for clinical trials in the U.S. It mentions the use of benchmarking for incidence and effect of protocol amendments in mid-sized to large pharmaceutical and biotechnology companies. It highlights cardiovascular and...

  • Credit for clinical trial data.  // Nature Genetics;Nov2012, Vol. 44 Issue 11, p1171 

    The author reflects on the sharing of clinical trial data in which data producers are separated from their data set. He states that existing authoring conventions should allow trial investigators to coauthor and take shared responsibility for data reanalyzes. An overview of the concerns of the...

  • EYE ON WASHINGTON. FDA addresses guidelines for pediatric clinical trials: Protecting rights, welfare of children is paramount. FOXHALL, KATHRYN // Contemporary Pediatrics;Dec2010, Vol. 27 Issue 12, p16 

    The article discusses the highlights of a workshop on pediatric clinical trials, held by the U.S. Food and Drug Administration (FDA) in 2010. The event emphasized the need to analyze the risks and benefits of pediatric cell and gene clinical therapy trials. Topics tackled include the best...

  • XenoPort announces FDA agreement on SPA for Phase III MS trial.  // PharmaWatch: CNS;Jun2011, Vol. 10 Issue 6, p19 

    The article reports on the agreement of XenoPort Inc. with the U.S. Food and Drug Administration (FDA) on a special protocol assessment (SPA) for Phase III multiple sclerosis (MS) trial. The biopharmaceutical company has signed a written agreement with the FDA for the pivotal Phase III clinical...

  • Warning Letter Study. Talele, Rajendra; Bowalekar, Suresh K. // Applied Clinical Trials;Oct2012, Vol. 21 Issue 10, p34 

    The article reports on the study conducted to evaluate warnings letters posted on the website of the U.S. Food and Drug administration for conduct of clinical trials from 1996 to 2010. It discusses the methodology of the study and list the stakeholders considered for the study including clinical...

  • Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma.  // Biomedical Market Newsletter;1/21/2012, Vol. 21, p1 

    The article informs that the U.S. Food & Drug Administration ("FDA") has provided guidance to Provectus Pharmaceuticals Inc. to submit its Phase 3 protocol for review, either via standard review or a request for Special Protocol Assessment ("SPA"). The guidance was in response to Provectus...

  • Lidocaine and Teething.  // Pediatrics for Parents;Jan/Feb2015, Vol. 30 Issue 1/2, p13 

    The article reports that a warning against the use of viscous lidocaine to treat teething pain in infants and children has been issued by the U.S. Food & Drug Administration (FDA).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics